Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker REGN
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Jason Pitofsky SVP Controller | REGN Regeneron Pharmaceuticals, Inc. | Sale | 179 | $950.76 | $170.2K Sale | Form 4 ↗ |
| Nov 4, 2026 | Jason Pitofsky SVP Controller | REGN Regeneron Pharmaceuticals, Inc. | Sale | 35 | $945.61 | $33.1K Sale | Form 4 ↗ |
| Nov 4, 2026 | Jason Pitofsky SVP Controller | REGN Regeneron Pharmaceuticals, Inc. | Sale | 108 | $944.22 | $102.0K Sale | Form 4 ↗ |
| Nov 4, 2026 | Jason Pitofsky SVP Controller | REGN Regeneron Pharmaceuticals, Inc. | Sale | 529 | $943.53 | $499.1K Sale | Form 4 ↗ |
| Nov 4, 2026 | Jason Pitofsky SVP Controller | REGN Regeneron Pharmaceuticals, Inc. | Sale | 1,215 | $942.31 | $1.1M Sale | Form 4 ↗ |
| Nov 4, 2026 | Jason Pitofsky SVP Controller | REGN Regeneron Pharmaceuticals, Inc. | Sale | 982 | $941.58 | $924.6K Sale | Form 4 ↗ |
| Nov 4, 2026 | Jason Pitofsky SVP Controller | REGN Regeneron Pharmaceuticals, Inc. | Sale | 575 | $940.46 | $540.8K Sale | Form 4 ↗ |
| Nov 4, 2026 | Jason Pitofsky SVP Controller | REGN Regeneron Pharmaceuticals, Inc. | Sale | 439 | $939.57 | $412.5K Sale | Form 4 ↗ |
| Nov 3, 2026 | Huda Y. Zoghbi Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 500 | $971.06 | $485.5K Sale | Form 4 ↗ |
| Nov 3, 2026 | Huda Y. Zoghbi Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 6,939 | $970.42 | $6.7M Sale | Form 4 ↗ |
| Nov 2, 2026 | Joseph J. Larosa EVP General Counsel and Secret | REGN Regeneron Pharmaceuticals, Inc. | Sale | 527 | $966.11 | $509.1K Sale | Form 4 ↗ |
| Nov 2, 2026 | Joseph J. Larosa EVP General Counsel and Secret | REGN Regeneron Pharmaceuticals, Inc. | Sale | 3,939 | $965.41 | $3.8M Sale | Form 4 ↗ |
| Nov 2, 2026 | George L. Sing Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 200 | $970.18 | $194.0K Sale | Form 4 ↗ |
| Nov 2, 2026 | George L. Sing Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 1,040 | $967.07 | $1.0M Sale | Form 4 ↗ |
| Nov 2, 2026 | George L. Sing Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 1,522 | $966.27 | $1.5M Sale | Form 4 ↗ |
| Nov 2, 2026 | George L. Sing Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 7,073 | $965.38 | $6.8M Sale | Form 4 ↗ |
| Nov 2, 2026 | George L. Sing Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 2,670 | $964.57 | $2.6M Sale | Form 4 ↗ |
| Nov 2, 2026 | George L. Sing Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 4,338 | $963.47 | $4.2M Sale | Form 4 ↗ |
| Nov 2, 2026 | George L. Sing Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 2,522 | $962.61 | $2.4M Sale | Form 4 ↗ |
| Nov 2, 2026 | George L. Sing Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 540 | $961.85 | $519.4K Sale | Form 4 ↗ |
| Nov 2, 2026 | George L. Sing Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 1,224 | $960.57 | $1.2M Sale | Form 4 ↗ |
| Nov 2, 2026 | Christine A. Poon Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 201 | $971.31 | $195.2K Sale | Form 4 ↗ |
| Nov 2, 2026 | Christine A. Poon Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 937 | $970.51 | $909.4K Sale | Form 4 ↗ |
| Nov 2, 2026 | Christine A. Poon Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 3,203 | $969.50 | $3.1M Sale | Form 4 ↗ |
| Nov 2, 2026 | Christine A. Poon Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 2,499 | $968.58 | $2.4M Sale | Form 4 ↗ |
| Nov 2, 2026 | Christine A. Poon Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 772 | $967.38 | $746.8K Sale | Form 4 ↗ |
| Nov 2, 2026 | Christine A. Poon Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 218 | $966.74 | $210.7K Sale | Form 4 ↗ |
| Oct 30, 2026 | Kathryn Guarini Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 400 | $900.00 | $360.0K Sale | Form 4 ↗ |
| Oct 30, 2026 | Marion McCourt EVP Commercial | REGN Regeneron Pharmaceuticals, Inc. | Sale | 1,132 | $869.43 | $984.2K Sale | Form 4 ↗ |
| Oct 30, 2026 | Michael S. Brown Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 1,929 | $875.00 | $1.7M Sale | Form 4 ↗ |
| Sep 3, 2026 | Marion McCourt EVP Commercial | REGN Regeneron Pharmaceuticals, Inc. | Sale | 1,131 | $857.39 | $969.7K Sale | Form 4 ↗ |
| Sep 2, 2026 | Kathryn Guarini Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 400 | $850.00 | $340.0K Sale | Form 4 ↗ |
| Sep 2, 2026 | Marion McCourt EVP Commercial | REGN Regeneron Pharmaceuticals, Inc. | Sale | 1,215 | $850.00 | $1.0M Sale | Form 4 ↗ |
| Aug 10, 2026 | Kathryn Guarini Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 400 | $800.00 | $320.0K Sale | Form 4 ↗ |
| Aug 10, 2026 | Huda Y. Zoghbi Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 800 | $800.00 | $640.0K Sale | Form 4 ↗ |
| Jul 2, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 200 | $650.15 | $130.0K Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 2 | $714.13 | $1,428 Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 1 | $712.09 | $712 Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 5 | $711.49 | $3,557 Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 2 | $710.87 | $1,422 Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 6 | $709.45 | $4,257 Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 4 | $707.40 | $2,830 Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 7 | $706.74 | $4,947 Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 14 | $705.56 | $9,878 Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 15 | $704.28 | $10.6K Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 24 | $703.46 | $16.9K Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 15 | $702.46 | $10.5K Sale | Form 4 ↗ |
| May 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 5 | $701.76 | $3,509 Sale | Form 4 ↗ |
| Apr 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 40 | $779.71 | $31.2K Sale | Form 4 ↗ |
| Apr 1, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | Sale | 4 | $778.24 | $3,113 Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 9:34 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances